Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

Vertex Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Hepatitis C

Opioid-Related Disorders

Treatments

Drug: telaprevir

Drug: buprenorphine/naloxone

Study type

Interventional

Funder types

Industry

Identifiers

NCT01275599

VX10-950-024

Details and patient eligibility

About

The purpose of this study is to investigate the drug-drug interaction potential between telaprevir and buprenorphine/naloxone. An understanding of the interaction potential will help to determine whether buprenorphine dose adjustments are necessary for patients who are concomitantly treated with telaprevir.

Telaprevir, in combination with other antiviral agents, is being investigated for the treatment of chronic hepatitis C virus infection. Buprenorphine/naloxone is used for maintainance therapy in patients with opioid dependence.

Enrollment

16 estimated patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males or females between the ages of 18 and 64 years, inclusive. Females must be of non-childbearing potential.
Receiving once daily buprenorphine/naloxone maintenance therapy at a stable dose not exceeding 24 mg/6 mg, respectively, for at least 2 weeks prior to screening.

Exclusion criteria

Illicit use of drugs such as cocaine, amphetamines and methylenedioxymethamphetamine (MDMA), barbiturates, benzodiazepines, tricyclic antidepressants, methadone or opiates/opioids (apart from buprenorphine).
Treatment with any investigational drug within the last 30 days, or 5 half-lives, whichever is longer.
Blood donation of 500 mL or more within the last 56 days.
Infected with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (HIV).